Stifel Financial Corp Exelixis, Inc. Transaction History

Stifel Financial Corp

$93.2 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$20.34 - $23.73 $24,062 - $28,072	-1,183 Reduced 6.88%	16,006 $359,000
Q1 2024 May 13, 2024	BUY	$20.17 - $23.93 $9,621 - $11,414	477 Added 2.85%	17,189 $407,000
Q4 2023 Feb 12, 2024	SELL	$19.25 - $24.13 $11,896 - $14,912	-618 Reduced 3.57%	16,712 $400,000
Q3 2023 Nov 13, 2023	BUY	$19.04 - $22.74 $9,634 - $11,506	506 Added 3.01%	17,330 $378,000
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $305,692 - $344,555	16,824 New	16,824 $321,000
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $850,580 - $988,743	-56,857 Reduced 46.9%	64,376 $1.03 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $314,995 - $447,382	-20,089 Reduced 14.22%	121,233 $1.9 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $55,773 - $74,065	-3,198 Reduced 2.21%	141,322 $2.94 Million
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $8,446 - $11,244	496 Added 0.34%	144,520 $3.28 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $99,601 - $137,581	6,288 Added 4.57%	144,024 $2.63 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $51,654 - $66,992	3,169 Added 2.35%	137,736 $2.91 Million
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $72,751 - $103,594	4,053 Added 3.11%	134,567 $2.45 Million
Q1 2021 May 14, 2021	BUY	$20.53 - $25.22 $295,981 - $363,596	14,417 Added 12.42%	130,514 $2.95 Million
Q4 2020 Feb 12, 2021	BUY	$18.39 - $24.8 $223,824 - $301,840	12,171 Added 11.71%	116,097 $2.33 Million
Q3 2020 Nov 16, 2020	BUY	$20.67 - $26.94 $106,781 - $139,172	5,166 Added 5.23%	103,926 $2.54 Million
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $40,754 - $67,891	-2,476 Reduced 2.45%	98,760 $2.35 Million
Q1 2020 May 14, 2020	SELL	$14.46 - $21.8 $193,344 - $291,487	-13,371 Reduced 11.67%	101,236 $1.73 Million
Q4 2019 Feb 13, 2020	SELL	$15.15 - $18.89 $519,099 - $647,246	-34,264 Reduced 23.02%	114,607 $2.02 Million
Q3 2019 Nov 13, 2019	SELL	$17.68 - $22.65 $541,450 - $693,656	-30,625 Reduced 17.06%	148,871 $2.63 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $307,991 - $402,682	-16,270 Reduced 8.31%	179,496 $3.84 Million
Q1 2019 May 14, 2019	BUY	$19.6 - $24.76 $2.07 Million - $2.61 Million	105,481 Added 116.83%	195,766 $4.66 Million
Q4 2018 Feb 13, 2019	BUY	$13.65 - $21.8 $374,323 - $597,821	27,423 Added 43.62%	90,285 $1.77 Million
Q3 2018 Nov 13, 2018	SELL	$15.87 - $22.4 $295,578 - $417,200	-18,625 Reduced 22.86%	62,862 $1.11 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $253,418 - $306,532	13,654 Added 20.13%	81,487 $1.75 Million
Q1 2018 May 11, 2018	SELL	$22.15 - $31.89 $776,822 - $1.12 Million	-35,071 Reduced 34.08%	67,833 $1.5 Million
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $725,203 - $925,734	29,930 Added 41.01%	102,904 $3.13 Million
Q3 2017 Nov 13, 2017	BUY	$23.35 - $29.24 $1.7 Million - $2.13 Million	72,974	72,974 $0

Others Institutions Holding EXEL

# of Institutions

503

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

Black Rock Inc. New York, NY

33.5M
Shares

$1.2 Billion
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

29.3M
Shares

$1.05 Billion
0.01% of portfolio
Farallon Capital Management LLC San Francisco, CA

25.4M
Shares

$913 Million
3.31% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

15.4M
Shares

$552 Million
0.63% of portfolio
State Street Corp Boston, MA

11.4M
Shares

$411 Million
0.01% of portfolio

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account